Ryan J. Watts - 03 Jan 2024 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
President and CEO, Director
Signature
/s/ Tyler Nielsen, by power of attorney
Issuer symbol
DNLI
Transactions as of
03 Jan 2024
Transactions value $
$0
Form type
4
Filing time
05 Jan 2024, 17:56:27 UTC
Previous filing
23 Aug 2023
Next filing
09 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Award $0 +89,520 +48.8% $0 272,957 03 Jan 2024 Direct F1, F2
holding DNLI Common Stock 2,242,604 03 Jan 2024 See footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNLI Stock Option (right to buy) Award $0 +268,560 $0 268,560 03 Jan 2024 Common Stock 268,560 $20.33 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2025 (the "Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.
F2 Includes 221,897 RSU's as of January 4, 2024.
F3 The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
F4 25% of the shares subject to the option shall vest on January 3, 2025, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.